Canine Osteosarcoma: Amputation, Chemotherapy, Costs, and Clinical Trials in 2026
By Brycen Levings | Editor: Tariq Shah · October 28, 2026
The Bone Cancer That's Already Spread by the Time You Find It
Osteosarcoma is the most common bone cancer in dogs, striking large and giant breeds most often. It's an aggressive disease with a hard truth at its center: even when the visible tumor is removed, microscopic cancer has almost always already spread by the time of diagnosis. That's why osteosarcoma has become one of the most active areas of canine cancer research — and why a clinical trial can matter so much here. Interestingly, canine osteosarcoma closely resembles the human equivalent, and so trials are also an area of specific interest as a translational model. Pet Trial Finder currently tracks 25 trials across accredited U.S. veterinary teaching hospitals. Here's what to know about the disease, standard care and its cost, and what's being studied now.
You're on the right path 🐾
Find Osteosarcoma trials in minutes, not in hours
What Is Canine Osteosarcoma?
Osteosarcoma is a malignant tumor of the bone. About 80% of cases arise in the limbs (appendicular osteosarcoma), typically near the wrist, shoulder, or knee, causing lameness and swelling. The rest occur in the skull, jaw, spine, or ribs (axial osteosarcoma). Fewer than 15% of dogs show visible spread at diagnosis — but more than 90% already carry microscopic metastasis, usually to the lungs. Understanding that single fact is the key to understanding treatment.
Standard Treatment and What It Costs
Because osteosarcoma is both intensely painful and prone to microscopic spread, standard care addresses both problems: local control to remove the source of pain, and systemic control to attack the micrometastasis. Amputation removes the primary tumor and, importantly, the pain, at $3,000 to $6,000 — and most dogs adapt remarkably well on three legs. Limb-sparing surgery, for select tumors in dogs who aren't good amputation candidates, is higher and more variable, often $6,000 or more. Carboplatin chemotherapy (four to six doses) is the standard follow-up to attack lung micrometastasis at $3,000 to $6,000. Palliative radiation with bisphosphonates offers pain relief when surgery isn't chosen, at $2,000 to $4,000. Specialist consultations run $200 to $500 per visit. The survival numbers make the case for combining surgery and chemotherapy: amputation alone yields a median survival of roughly 4 to 5 months, because the lung metastasis is untreated. Amputation plus carboplatin extends median survival to roughly 10 to 12 months, with a meaningful share of dogs reaching a year or beyond. Even so, most dogs ultimately succumb to lung metastasis within two years — which is precisely the ceiling that trials aim to break.
Clinical Trials: What Is Being Studied
While standard care—typically amputation paired with systemic chemotherapy—can extend high-quality time, long-term survival rates have remained frustratingly static for decades. Clinical trials bridge this critical gap by providing access to novel immunotherapies, targeted agents, and innovative localized treatments that aim to prevent or delay metastatic recurrence. Participating in a trial gives dogs access to cutting-edge medicine while actively helping advance the next generation of veterinary oncology. ELIAS Cancer Immunotherapy achieves this using the body’s own cancer cells to create an autologous vaccine. By using an apheresis step to extract the immune cells followed by an expansion of the T-cells, efficacy of the vaccine is considerably increased. Anti-metastatic drug combinations pairing a targeted drug (toceranib) with a blood-pressure medication (losartan) are being investigated specifically to interfere with spread to the lungs. mTOR inhibitors such as rapamycin, repurposed to slow metastatic progression, have been studied in large multi-center canine trials. And novel limb-sparing and radiopharmaceutical techniques — including bone-seeking radioactive agents — aim to improve local control.
Who Qualifies for an Osteosarcoma Trial?
Most trials require a confirmed diagnosis (imaging plus biopsy or aspirate), staging to check for visible spread, and adequate organ function. Some enroll dogs at the time of amputation (the adjuvant setting); others accept dogs whose disease has already metastasized and who need a new option. Because timing matters so much in osteosarcoma, applying early — around the time of diagnosis — gives you the most choices.
How Trial Costs Compare to Standard Treatment
Fully funded osteosarcoma trials often cover the investigational therapy, trial-specific imaging, and specialist monitoring. Given that standard surgery-plus-chemotherapy runs $6,000 to $12,000, that can be a substantial offset — while giving your dog access to therapies aimed squarely at the metastasis that standard care struggles to control. Pet Trial Finder checks your dog against all 25 Osteosarcoma trials — plus the full database of 133 trials across 39 cancer types — in a single application. Results in hours, not weeks.